Welcome to Markets Desk, your midday read on what's moving markets and policy.
The Federal Reserve's next chapter is drawing serious scrutiny. Kevin Warsh, tipped as the incoming Fed chair, has long been a vocal critic of quantitative easing, and he's on record calling the central bank's pandemic-era response the largest policy error in fifty years. For Wall Street, which has grown comfortable leaning on accommodative monetary conditions, a Warsh-led Fed signals a harder line ahead, with implications for rate expectations and risk appetite across asset classes.
Shifting to pharma, AstraZeneca took a setback on its breast cancer drug camizestrant after the FDA extended its PDUFA review date, requesting additional data to support the new drug application in combination with a CDK four slash six inhibitor for first-line treatment. Regulatory delays of this kind rarely sink a program outright, but they reset the commercial timeline and introduce uncertainty that tends to weigh on biotech valuations near term.
And in an area drawing increasing Pentagon attention, defense industry operators recently test-fired a seventy millimeter precision rocket from a logistics resupply drone, with the US Army watching. The demonstration signals a broader push to give battlefield drones rapidly swappable payloads, blurring the line between supply and strike capability in ways that could reshape procurement priorities significantly.
That's the tape. Markets Desk, signing off the floor.
